REFERENCES
- Krishnan J, Danon AD, Frizzera G. Reactive lymphadenopathies and atypical lymphoproliferative disorders. Hematopathology. 1992;99:385–396.
- Plavcović H, Schutz VV, Rossler J. Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer. 2001;92:756–760.
- Salgado R, Benoy I, Weytjens R. Serum vascular endothelial growth factor load and interleukin-6 in cancer patients. Br J Cancer. 2000;82:1895–1897.
- Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res. 1999;5:487–490.
- Ben Arush MW, Schenzer P, Maurice S, . Serum vascular endothelial growth factor as a significant marker of treatment response in pediatric malignancies. Pediatr Hematol Oncol. 2005;22:513–524.
- El Houseini ME, Abdel Azim SAF, El Desouky GI. Clinical significance of vascular endothelial growth factor (VEGF) in sera of patients with pediatric malignancies. J Egypt Nat Cancer Inst. 2004;16:57–61.
- Yetgkin S, Yenicesu I, Cetin M. Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymph. 2001;42:83–88.
- Bellamy WT, Richter L, Frutiger Y, . Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728–733.
- Wróbel T, Mazur G, Dzięgiel P, . Density of intranodal lymphatics and VEGF-C expression in B-cell lymphoma and reactive lymph nodes. Fol Histochem Cytobiol. 2006;44:43–47.
- Xia Y, Sun XF, Zhang CQ, . Primary study of relationship between serum level of VEGF and non-Hodgkin's lymphoma in children and adolescent patients [abstract]. Ai Zheng. 2004;23:1448–1450.
- Poon RTP, Tat-Fan S, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001;19:1207–1225.
- Kadowaki I, Ichinohasama R, Herigae H, . Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. Br J Hematol. 2005;130:869–877.
- Citak EC, Oguz A, Karadeniz C, Akyurek N. Role of gelatinases (MMP-2 and MMP-9), TIMP-1, vascular endothelial growth factor (VEGF), and microvessel density on the clinicopathological behavior of childhood non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2008;25:55–66.
- Citak EC, Oguz A, Karadeniz C, Akyurek N. Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma. Pathol Res Pract. 2008;204:89–96.
- Verheul HMW, Hoekman K, Luykx-de Bakker S. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res. 1997;3:2187–2190.
- Pinedo HM, Verheul HMW, D’Amato RJ, . Involvement of platelets in tumor angiogenesis? Lancet. 1998;352:1775–1776.
- Webb NJA, Bottomley MJ, Watson CJ, . Vascular endothelial growth factor (VEGF) is released from during blood clotting: implications for measurment of circulating VEGF levels in clinical disease. Clin Sci. 1998;94:395–404.
- Karkkainen MJ, Petrova TU. VEGF receptors in the regulation of angiogenesis. Oncogene. 2000;19:5598–5601.
- Koster A, Raemaekers JM. Angiogenesis in malignant lymphoma. Curr Opin Oncol. 2005;17:611–616.
- Ferrara N. Role of VEGF in the regulation of angiogenesis. Kidney Int. 1999;56:794–814.
- Fukushima N, Satoh T, Sano M, . Angiogenesis and mast cells in non-Hodgkin's lymphoma: a strong correlation in angioimmunoblastic T-cell lymphoma. Leuk Lymph. 2001;42:709–720.
- Khnytkin D, Troen G, Berner JN, . The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma. J Pathol. 2006;208:431–438.
- Arush BMW, Schenzer P, Maurice S, . Serum-VEGF as a significant merker of treatment response in Hodgkin Disease. In: Proceedings of the 38th Annual Conference of the SIOP; September 18–21, 2006; Geneva, Switzerland.
- Visal Okur F, Karadeniz C, Buyukpamukcu, M . Angiogenic growth factors and endostatin in pediatric lymphomas. In: Proceedings of the 38th Annual Conference of the SIOP; September 18–21, 2006; Geneva, Switzerland.